Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2018
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms FLEET-2
- 02 Mar 2018 Pooled analysis of FLEET and FLEET2 studies has been presented in UMIN registry record (Unique ID issued by UMIN:UMIN000031233; Receipt No.: R000035663).
- 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 09 Jun 2012 Additional lead investigator(Hideyuki Mishima) identified as reported by University Hospital Medical Information Network - Japan record.